Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Apple Turns 50: From Garage Startup to AI Crossroads 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
PETALUMA, Calif., July 25, 2017 -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal first quarter 2018, ended June 30, 2017, will be released after the U.S. markets close on August 8, 2017. The earnings release will be followed by a conference call at 1:30 p.m. PDT on August 8, 2017, to discuss fiscal first quarter results.
Individuals interested in participating in the conference call may do so by dialing 877-303-7607 for domestic callers or 973-638-3203 for international callers. Those interested in listening to the conference call live via the internet may do so at http://ir.sonomapharma.com/events.cfm.
A telephone replay will be available for seven days following the conclusion of the call by dialing 855-859-2056 for domestic callers, or 404-537-3406 for international callers, and entering conference code 47563590. A webcast replay will be available on the site at http://ir.sonomapharma.com/events.cfm for one year following the call.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals (formerly Oculus Innovative Sciences) is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The company’s products, which are sold throughout the United States and internationally, have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com.
Media and Investor Contact: Sonoma Pharmaceuticals, Inc. Dan McFadden VP of Public and Investor Relations (425) 753-2105 [email protected]
